NCT04119024 2026-03-17Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsStanford UniversityPhase 1 Recruiting18 enrolled
NCT03074513 2026-03-11Atezolizumab and Bevacizumab in Treating Patients With Rare Solid TumorsM.D. Anderson Cancer CenterPhase 2 Active not recruiting133 enrolled
NCT05199584 2026-03-05A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function MutationsEndeavor Biomedicines, Inc.Phase 2 Completed20 enrolled
NCT00006368 2013-05-01Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent CancerNovartisPhase 1 Completed60 enrolled